D. Boral Capital Reiterates “Buy” Rating for Clene (NASDAQ:CLNN)

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $23.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 217.37% from the stock’s current price.

A number of other research firms have also weighed in on CLNN. Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a report on Friday, March 13th. Weiss Ratings downgraded shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Clene Price Performance

Shares of NASDAQ:CLNN opened at $7.25 on Monday. The firm has a market capitalization of $85.37 million, a price-to-earnings ratio of -2.86 and a beta of 0.89. Clene has a one year low of $2.28 and a one year high of $13.50. The company’s fifty day moving average price is $5.68 and its 200-day moving average price is $6.47.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.03 million. As a group, equities research analysts expect that Clene will post -1.99 EPS for the current year.

Insider Transactions at Clene

In other Clene news, major shareholder Chidozie Ugwumba sold 5,736 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $6.08, for a total transaction of $34,874.88. Following the completion of the transaction, the insider owned 277,569 shares of the company’s stock, valued at $1,687,619.52. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 159,084 shares of company stock worth $931,704 over the last ninety days. 28.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SymBiosis Capital Partners LLC purchased a new position in shares of Clene during the fourth quarter valued at approximately $4,523,000. Scoggin Management LP lifted its position in Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in shares of Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after buying an additional 99,481 shares during the period. PEAK6 LLC purchased a new stake in shares of Clene during the fourth quarter valued at approximately $294,000. Finally, State Street Corp boosted its stake in Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after acquiring an additional 17,300 shares during the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).